ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

Idenix: 89% of Patients in Hep C Trial Arm Achieved Viral Suppression

By Ben Fox Rubin Biopharmaceutical firm Idenix Pharmaceuticals Inc. (IDIX) has provided some results from an ongoing Phase 2b study of its lead hepatitis C drug, IDX184, showing positive suppression of the virus. Shares jumped 15% after hours Tuesday to $10.79, as the company's stock often moves sharply following reports related to its or its competitors' hepatitis C drugs. As of the market close, the shares were up 26% so far this year. Idenix is among a handful of companies scrabbling to develop a marketable all-oral Hepatitis C drug, with demand for the treatment expected to be worth billions of dollars a year. Gilead Sciences Inc. (GILD) is a main competitor of Idenix in the race develop such a drug; it spent $11 billion to buy Pharmasset this year, in part to obtain its lead hepatitis C drug candidate, GS-7977. In the Idenix study, Idenix used a mix of its IDX184 with older medications interferon and ribavirin. In all, 31 patients were enrolled and 18 reached extended rapid virologic response, which is when the virus becomes undetectable at four weeks of treatment and again at 12 weeks of treatment. Of those 18 patients, nine were given additional treatments for 12 more weeks. All but one of them achieved sustained virologic response, or undetectable traces of the virus, a month after treatment ended. The other nine patients and those who didn't reach extended rapid virologic response are continuing a regimen of 36 weeks of treatment. Write to Ben Fox Rubin at

Stock News for Gilead Sciences (GILD)
05/27/201614:59:00SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement...
05/27/201611:35:00SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On...
05/27/201607:25:00European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (S...
05/25/201612:16:17Current Report Filing (8-k)
05/24/201618:00:00Gilead Names New Operating Chief
05/24/201616:30:00Gilead Sciences Announces Appointment of Kevin Young CBE as Chief...
05/20/201617:00:00Gilead Sciences to Present at the UBS Global Healthcare Conference...
05/17/201614:37:56Current Report Filing (8-k)
05/13/201619:47:09Statement of Changes in Beneficial Ownership (4)
05/13/201619:45:08Statement of Changes in Beneficial Ownership (4)
05/13/201619:43:42Statement of Changes in Beneficial Ownership (4)
05/13/201619:42:38Statement of Changes in Beneficial Ownership (4)
05/13/201619:41:35Statement of Changes in Beneficial Ownership (4)
05/13/201619:40:19Statement of Changes in Beneficial Ownership (4)
05/13/201619:39:28Statement of Changes in Beneficial Ownership (4)
05/13/201617:37:02Confidential Treatment Order (ct Order)
05/13/201617:28:00Confidential Treatment Order (ct Order)
05/10/201617:34:28Statement of Changes in Beneficial Ownership (4)
05/10/201617:30:13Statement of Changes in Beneficial Ownership (4)
05/10/201617:21:41Statement of Changes in Beneficial Ownership (4)

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations